Clinical Trial

A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 20, 2023 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is an open-label, single arm Phase II study designed to evaluate the efficacy and safety of adebelizumab combined with carboplatin/Cisplatin plus (+) etoposide and concurrent radiotherapy in the first-line treatment of patients with extensive stage oligometastatic small cell lung cancer.
Trial Details
NCT Number NCT06177925
Lead Sponsor Nanfang Hospital, Southern Medical University
Collaborators: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Conditions Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site, Neoplasms, Lung Diseases, Respiratory Tract Diseases, Carcinoma, Bronchogenic, Bronchial Neoplasms +2 more
Enrollment 62 participants
Start Date 2023-12-10
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2023-12-20